These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38040479)

  • 1. Effect of implementation strategies on pre-exposure prophylaxis persistence among female sex workers in South Africa: an interrupted time series study.
    Rao A; Mhlophe H; Pretorius A; Mcingana M; Mcloughlin J; Shipp L; Baral S; Hausler H; Schwartz S; Lesko C
    Lancet HIV; 2023 Dec; 10(12):e807-e815. PubMed ID: 38040479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
    Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
    Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence on oral pre-exposure prophylaxis (PrEP) among female sex workers in eThekwini, South Africa, 2016-2020.
    Rao A; Mhlophe H; Comins C; Young K; Mcingana M; Lesko C; Mulumba N; Baral S; Hausler H; Schwartz S
    PLoS One; 2022; 17(3):e0265434. PubMed ID: 35290421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
    Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
    Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
    Moodley D; Lombard C; Govender V; Naidoo M; Desmond AC; Naidoo K; Mhlongo O; Sebitloane M; Newell ML; Clark R; Rooney JF; Gray G;
    Lancet HIV; 2023 Mar; 10(3):e154-e163. PubMed ID: 36746169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
    Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M
    J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
    Celum CL; Bukusi EA; Bekker LG; Delany-Moretlwe S; Kidoguchi L; Omollo V; Rousseau E; Travill D; Morton JF; Mogaka F; O'Malley G; Barnabee G; van der Straten A; Donnell D; Parikh UM; Kudrick L; Anderson PL; Haberer JE; Wu L; Heffron R; Johnson R; Morrison S; Baeten JM;
    J Int AIDS Soc; 2022 Jul; 25(7):e25962. PubMed ID: 35822945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
    Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
    PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of Oral HIV Pre-Exposure Prophylaxis (PrEP) and Associated Factors among Female Sex Workers in Tanga, Tanzania.
    Martin VO; Tesha NA; Sunguya BF
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.
    Laurent C; Dembélé Keita B; Yaya I; Le Guicher G; Sagaon-Teyssier L; Agboyibor MK; Coulibaly A; Traoré I; Malan JB; De Baetselier I; Eubanks A; Riegel L; Rojas Castro D; Fayé-Ketté H; Koné A; Diandé S; Dagnra CA; Serrano L; Diallo F; Mensah E; Dah TTE; Anoma C; Vuylsteke B; Spire B;
    Lancet HIV; 2021 Jul; 8(7):e420-e428. PubMed ID: 34048794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
    Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
    PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa.
    Rao A; Lesko C; Mhlophe H; Rucinski K; Mcingana M; Pretorius A; Mcloughlin J; Baral S; Beyrer C; Hausler H; Schwartz S
    AIDS; 2023 May; 37(6):977-986. PubMed ID: 36723509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial.
    Haberer JE; Bukusi EA; Mugo NR; Pyra M; Kiptinness C; Oware K; Garrison LE; Thomas KK; Musinguzi N; Morrison S; Anderson PL; Ngure K; Baeten JM;
    Lancet HIV; 2021 Mar; 8(3):e130-e137. PubMed ID: 33662265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "I am still negative": Female sex workers' perspectives on uptake and use of daily pre-exposure prophylaxis for HIV prevention in South Africa.
    Eakle R; Bothma R; Bourne A; Gumede S; Motsosi K; Rees H
    PLoS One; 2019; 14(4):e0212271. PubMed ID: 30964874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis.
    Stone J; Bothma R; Gomez GB; Eakle R; Mukandavire C; Subedar H; Fraser H; Boily MC; Schwartz S; Coetzee J; Otwombe K; Milovanovic M; Baral S; Johnson LF; Venter WDF; Rees H; Vickerman P
    J Int AIDS Soc; 2023 Feb; 26(2):e26063. PubMed ID: 36807874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.